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Abstract
There is increasing interest in the identification of biomarkers that could predict neurological outcome following a spinal cord
injury (SCI). Although initial American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade is a good indicator of
neurological outcome, for the patient and clinicians, an element of uncertainty remains. This preliminary study aimed to assess
the additive potential of routine blood analytes following principal component analysis (PCA) to develop prognostic models for
neurological outcome following SCI. Routine blood and clinical data were collected from SCI patients (n= 82) and PCA used to
reduce the number of blood analytes into related factors. Outcome neurology was obtained from AIS scores at 3 and 12 months
post-injury, with motor (AIS and total including all myotomes) and sensory (AIS, touch and pain) abilities being assessed
individually. Multiple regression models were created for all outcome measures. Blood analytes relating to ‘‘liver function’’ and
‘‘acute inflammation and liver function’’ factors were found to significantly increase prediction of neurological outcome at both
3 months (touch, pain, and AIS sensory) and at 1 year (pain, R2 increased by 0.025 and total motor, R2 increased by 0.016). For
some models ‘‘liver function’’ and ‘‘acute inflammation and liver function’’ factors were both significantly predictive, with the
greatest combinedR2 improvement of 0.043 occurring for 3 month pain prediction. These preliminary findings support ongoing
research into the use of routine blood analytes in the prediction of neurological outcome in SCI patients.
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Introduction
Relatively few studies have sought to identify prognosticbiomarkers for spinal cord injury (SCI), although in recent
years more early/discovery phase work in this research area has
been published.1–4 However, this field of study is considered to be
in its infancy, and no biomarkers to date have been examined
routinely in SCI patients.5 Importantly, any potential new bio-
markers must demonstrate their utility in the context of the cur-
rently used prognostic indicators, of which the severity of the initial
injury is the most indicative of long-term neurological recovery;
however, age, medical history/medication, polytrauma, and gender
are also relevant.6,7 Further, care must be taken to consider con-
founding variables such as diet, obesity, diabetes, and smoker
status.8–10
There is a growing appreciation of the value of analyzing rou-
tinely collected patient samples for relevant biomarkers in various
fields, such as breast cancer, liver fibrosis, osteoporosis, and car-
diovascular disease.11–14 However, to our knowledge, there are no
comprehensive studies examining the utility of multiple routinely
measured biomarkers in SCI patients, despite the success of such
techniques in the fields of Alzheimer’s disease, cancer, and oste-
oarthritis.15–17 Routinely measured blood biomarkers include in-
dicators of organ function, bone profile measures, infection and
inflammation, nutritional status, and overall blood counts. In other
neurological conditions, some of these routinely measured bio-
markers have been associated with long-term neurological out-
comes. For example, serum albumin concentrations are routinely
measured to determine liver function and/or dietary status; how-
ever, altered albumin concentrations both during18 and in the acute
phase following ischemic stroke19 have been associated with neu-
rological state post-stroke. Moreover, serum albumin levels have
been found to relate to outcome following traumatic brain injury
(TBI),20 intravenous immunoglobulin-treated Guillain–Barre
Syndrome,21 and amyotrophic lateral sclerosis (ALS),22 in addition
to serum creatinine concentrations, which have been shown to
correlate with ALS outcome.22
This study aims to assess routinely collected blood samples ta-
ken within 2 weeks of SCI (acute setting) and compare samples
across patients with their neurological outcomes at 3 and 12 months
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post-injury. These data, in combination with the aforementioned
known prognostic indicators (baseline neurology, age, gender, di-
abetes status), will form the basis of a prognostic model, similar to
those developed for TBI,23 that can be refined in future work.
Methods
Summary of patients included in study
We retrospectively studied records from 99 patients who had
been admitted to the Midlands Centre for Spinal Injuries (MCSI)
between 1980 and 2017. These patients were from a cohort who had
previously consented for their patient records to be accessed as
part of two other ethically approved studies (National Research
Ethics Service [NRES] Committee North West Liverpool East
[11/NW/0876] and NRES Committee West Midlands, Stafford-
shire [13/WM/0158]). Seventeen patients were excluded: one pa-
tient because of previous acute myeloid leukemia, the remaining
because of incomplete data on initial and 3 month follow-up In-
ternational Standards for Neurological Classification of SCI
(ISNCSCI) AIS (American Spinal Injury Association [ASIA] Im-
pairment Scale) scores, or their injuries being non-traumatic.
Eighty-two SCI patients (age range 17–81 years) whose initial
blood samples were taken on average at 7 – 4 days following
traumatic injury were included in the statistical analyses (Table 1).
The blood data were reviewed, and information regarding full
blood counts, urea/electrolytes, liver function, bone profile mea-
sures including magnesium, C-reactive protein (CRP), and other
parameters such as prothrombin time were recorded (Table S1).
Routine blood analyses were conducted in the Haematology and
Biochemistry department located at the Robert Jones and Agnes
Hunt Orthopaedic Hospital. Hematology analyses were performed
on either a Beckman Coulter LH-500 or a Sysmex XN-1000, whereas
biochemical analyses used VITROS slides (dry multi-layered
chemistry slides) in conjunction with the VITROS 5,1 FS Chemistry
System to measure albumin, alanine transaminase (ALT), calcium,
creatinine, gamma-glutamyl transferase (GGT), potassium, mag-
nesium, sodium, phosphate, total bilirubin, total protein, and urea.
AIS scores were collated and broken down into muscle function
(AIS motor [M]) and sensory (AIS Sens) scores with the sensory
scores being split further into touch (T) and pain (P) scores. AIS
scores for muscle function focus on 10 key muscle groups,24 so
whenever possible, a functional score for all muscle groups (total
M) was collated.
Additional information that could impact on the blood analytes
was included in the predictive model analysis. Comorbidities were
coded and represented the number that the patient currently had,
and included musculoskeletal, respiratory, abdominal, cardiovas-
cular, and mental health issues. The presence of vertebral fractures
and the necessity for surgical intervention following injury were
Table 1. Summary of Clinical Information
for the Patient Cohort
SCI Patients (n)
Age (mean –SD) 44.4 – 17.2 years 82
Males 60
Females 22
Level of injury:
Cervical 47
Thoracic 27
Lumbar 8
Injury level:
Above L1 72
At L1 6
Below L1 2
Neurologically intact 2
Initial AIS score:
A 34
B 9
C 26
D 11
E 2
Outcome AIS score:
A 29
B 7
C 15
D 29
E 2
Complete 34
Incomplete 46
Neurologically intact 2
Tetraplegic 46
Paraplegic 34
Improvers:
A/B 3
A/C 2
B/C 2
B/D 3
C/D 15
CCS patients 11
Vertebral fracture 67
Surgery required following injury 34
Initial infection 7
Diabetes 8
Pressure sores 9
*Comorbidities:
None 60
One 11
Two 7
Three 3
**Smoker:
No 47
Previous 13
Yes 20
**Alcohol:
No 16
Yes 64
Medications with potential to impact blood analytes:
No 34
Yes, but no known impact 18
Yes, and potential to impact 30
(continued)
Table 1. (Continued)
SCI Patients (n)
Impact of existing ailments on blood samples:
None 46
One ailment 19
Two or more ailments 17
*Polytrauma 47
Non-polytrauma 34
British 70
*Asterisks indicate that information regarding these parameters were
unavailable for one (*) or two (**) of the patients respectively.
Characteristics in italics were not inputted into the multiple regression
models.
SCI, spinal cord injury; SD, standard deviation; AIS, American Spinal
Injury Association (ASIA) Impairment Scale; CCS, central cord syndrome.
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also recorded. As to whether patients had an infection, diabetes, or
pressure sores, were smokers, or had previously smoked and/or
drunk alcohol were noted. If the patient had sustained a polytrauma
at the time of the SCI, such as other broken bones including ad-
ditional fractured vertebrae, severe contusions, or burns, this was
documented. If the patient was receiving medications in addition to
the typical painkillers and anti-stomach acid and anticoagulant
preparations received following a SCI, these were recorded and
grouped into those that may have influenced blood biomarker
outcome such as statins, steroids, certain antibiotics, and antide-
pressants, and those that would likely not.
Statistical analysis
Statistical calculations were performed with IBM SPSS Statis-
tics version 24.0 (SPSS Inc., Chicago, IL). Data were assessed for
normality using both the Kolmogorov–Smirnov and Shapiro–Wilk
tests. As the majority of data were not normally distributed, non-
parametric tests were performed. Clinical features with binary
outcomes that could potentially influence levels of the various
blood biomarkers, such as gender and infection, were assessed via
the Mann–Whitney U test (exact, two tailed) whereas features with
more than two possible outcomes, such as injury level, were as-
sessed via Kruskal–Wallis. All variables were assessed for signi-
ficant associations using Kendall’s tau for non-parametric rank
correlations.
In total, five neurological outcome measures were assessed: total
M (total muscle function), T (touch), P (pain), AIS M (muscle
function focused on key groups), and AIS Sens (sensory function, T
and P combined) at*3 and 12 months post-injury, to account for
the potential of the blood analytes to predict subtle improve-
ments/worsening in motor or sensory function.
As the number of blood analytes being assessed was relatively
high compared with the number of participants, principal compo-
nent analysis (PCA) was performed to determine the possibility of
reducing the number of blood analytes into related factors. Factor
analysis via PCA was conducted on both blood analytes and initial
neurological measures following removal of any high (r > 0.8) or
low (r< 0.3) correlations via oblique rotation (direct oblimin). The
resulting factors were named to reflect their most appropriate bio-
logical function.
The potential of individual blood analytes and factors generated
from PCA were assessed in combination with compounding clin-
ical factors (Table 1) and either the initial neurological scores
(M, T, P, AIS M, and AIS Sens) or the appropriate neurological
factor generated from PCA via multiple regression analysis to de-
termine their potential to predict outcome neurology at 3 and 12
months. Values of p< 0.05 were considered statistically significant.
Statistical analyses and p values were not adjusted for multiple
testing and should be interpreted accordingly.
Results
All 82 patients had undergone a traumatic SCI: 33 patients had
undergone a fall from a height or step; 29 patients had been in-
volved in a motor vehicle incident (car, motorbike, go-karting); 15
patients were injured during sporting activities (horse riding,
climbing, skateboarding, skiing, air sports, cycling, rugby, fair-
ground ride); 4 patients had been struck by a falling weight; and 1
patient had been assaulted.
There were 34 patients classed as ISNCSCI AIS A, 9 patients
classed as AIS B, 26 patients classed as AIS C, 11 patients classed
as AIS D, and 2 patients classed as neurologically intact following
their initial neurological examination following injury. All patients
had follow-up neurological scores; 79 patients at *3 months and
72 patients at 1 year. Of the 82 patients, 25 were termed ‘‘improvers,’’
as their ISNCSCI AIS score improved by at least one level (Table 1).
Seventy-five percent of patients included in the study were
males, with most injuries occurring at the cervical level (57%) and
the least number of injuries occurring in the lumbar region (10%).
Most patients (41%) sustained an AIS A complete injury (for the
purposes of this study AIS A improvers were described as com-
plete). The second most common injury was AIS C (32%). The
majority of patients (56%) had an incomplete injury and 56% were
tetraplegic. Although 6% of AIS A patients improved to become
AIS B (4%) or C (2%), and 2% of AIS B patients became AIS C, the
greatest percentage of improvers occurred in the AIS C group, with
18% of patients becoming AIS D.
Central cord syndrome (CCS) occurred in 13% of patients,
whereas vertebral fractures were detected in 82% of patients.
Surgery was required in 41% of cases whereas initial infections
(9%), diabetes (10%), and pressure sore incidences (11%) were
relatively uncommon. The majority of patients had no comorbid-
ities (74%), whereas the remaining had one (14%), two (9%), or
three (4%) comorbidities. Of these existing medical conditions,
most had no effect on blood analytes (56%), whereas medications
that could impact on these measures were being taken by just over
one third of patients (37%). More than half of patients (58%) had
sustained polytrauma, and the majority had never smoked, whereas
80% regularly drank alcohol.
Table S1 provides a summary of the neurological scores and
various analytes routinely measured in SCI patients on admission.
In particular, red blood cell (RBC) measures had a tendency to be
lower than the normal range whereas white blood measures tended
to be higher. Most electrolytes fell within the normal range, but
liver function and bone profile measures tended to be higher, with
albumin and total protein levels appearing to be lower than normal
values. The inflammatory marker, CRP, was also higher in the
majority of SCI patients, in comparison with normal levels.
Assessment of categorical features that could impact on the
blood analytes demonstrated typically associated differences with
respect to gender on RBC measures, albumin, total protein, and
prothrombin time but also creatinine. Significant differences in
RBC measures were also found in patients with CCS or injuries
causing tetraplegia compared with paraplegia, different levels of
injury or complete versus incomplete injury, vertebral fracture
presence, surgical intervention following injury, or with co-
morbidities. Smoking and alcohol affected red cell distance width,
and mean cell haemoglobin, respectively. Urea was found to be
significantly different in improvers (7.2– 2.8 mmol/L) compared
with non-improvers (5.8– 1.8 mmol/L), and was affected by level
and presence of vertebral fracture, whereas albumin discriminated
among initial AIS grades. CRP was found to be affected by level
and severity of injury, surgical intervention, polytrauma and co-
morbidities, existing ailments, and medications. Calcium levels were
affected by patients having diabetes and polytrauma, whereas so-
dium, which was also affected by diabetes, was impacted by alcohol
intake as well. The presence of comorbidities and pressure sores was
found to affect potassium levels. ALT, a marker of liver health, was
lower in tetraplegics (58.8– 38.2 u/L) than in paraplegics
(79.7– 61.0 u/L) and was also affected by the patient having had
surgery following injury (as were other markers of liver function
such as GGT and prothrombin time), smoking, pressure sores, and
pre-existing conditions that also affected prothrombin time.
Hematological indices were impacted by surgery (platelets and
mononuclear cells), diabetes (neutrophils), and pressure sores
(platelets). Surgery also affected creatinine and alkaline phospha-
tase (AP) levels. Age was also found to be a contributory feature
with regard to injury level and severity, vertebral fracture, surgical
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intervention, polytrauma, diabetes, comorbidities, and additional
medications. Only seven patients had an initial infection on ad-
mission; therefore, significant differences need to be interpreted
with caution, but urea, albumin, total protein, ALT, and GGT were
found to be different between patients with and without an initial
infection.
The various blood analytes were assessed against initial (Table 2)
and outcome (Table 3) neurological measures at 3 and 12 months
post-injury to determine whether any significant correlations existed.
No significant correlations between the initial or outcome neuro-
logical scores at 3 and 12 months post-injury and the following blood
analytes were found: mean corpuscular volume, red cell distance
width, platelets, lymphocytes, mononuclear cells, eosinophils, urea,
ALT, total bilirubin, CRP, phosphate, adjusted calcium, magnesium
and international normalized ratio (INR).
Thirteen blood analytes correlated with some or all of the initial
neurology scores (Table 2). Some blood analytes correlated with
only those scores associated with sensory outcome, such as white
blood cells (WBC), creatinine, and prothrombin time, whereas
others were associated only with muscle function (hemoglobin and
AP levels). The remaining measures correlated with both sensory
and muscle function, in particular, RBC measures (RBC, hemato-
crit and mean cell hemoglobin [MCHb]) and albumin, total protein,
sodium, and calcium levels. The strongest correlation occurred between
total protein and initial AIS M (Kendall’s tau = 0.355, p < 0.000).
Table 3 summarizes the significant correlations between the
blood analytes and outcome neurology. RBC was the only blood
analyte that correlated with all of the outcome measures at both 3
and 12 months post-injury. Hemoglobin, hematocrit, total protein,
and calcium correlated with all outcome measures at 3 months.
Hemoglobin and hematocrit only correlated with AIS M at 1 year
and calcium correlated with T and AIS Sens at 1 year, whereas total
protein correlated with all 1 year outcome measures except for the
total M score. Albumin and basophils correlated with all outcome
measures at 3 months except for the P score, and basophils also
correlated with all outcome measures at 1 year except for the total
M score, whereas at 1 year, albumin only correlated with the muscle
function scores (total M and AIS M). Of the electrolytes, sodium
and potassium correlated with one neurological outcome at the
3 month time point, AIS M and Total M respectively. GGT only
correlated with sensory outcomes at 1 year (T and AIS Sens) and
age correlated with both sensory and muscle function measures at 3
and 12 months post-injury. The strongest correlation between blood
analytes and outcome neurology was between RBC and 1 year AIS
M (Kendall’s tau = 0.352, p< 0.001).
PCA was conducted to reduce the number of blood analytes for
predictive modeling analysis. Initially, correlation matrices were
generated for all neurological and blood analyte measures and any
measures that had correlation coefficients >0.8 were applied to the
PCA independently of each other, whereas measures that correlated
with all other measures with coefficients <0.3 were excluded. High
correlations (> 0.8) were only found between the initial measures of
total M, P, and T (individual measures) with initial AIS M and AIS
Sens (combined) scores. The individual measures were put into
PCA-I whereas the combined AIS scores were input into PCA-C.
The Kaiser–Meyer–Olkin (KMO) measure verified the sampling
adequacy for the analysis, (KMO = 0.693 and 0.694 for PCA-I and
PCA-C respectively) and all KMO values for each measure/analyte
was >0.67, which is above the acceptable limit of 0.525 (analytes
that did not reach this limit were omitted from the PCA). Bartlett’s test
of sphericity was v2 (120)=451.075, p<0.001 and v2 (66)=272.967,
p < 0.001 respectively, indicating that correlations between items
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were sufficiently large for PCA. An initial analysis was run to
obtain eigenvalues for each factor in the data. Six and five factors
for PCA-I and PCA-C, respectively, had eigenvalues above Kaiser’s
criterion of 1, and in combination explained 80.02% and 81.35%
of the variance, respectively. Additionally, scree plots showed
inflexions that justified retaining the factors up to 6 and 5. Given
the sample size, the convergence of the scree plot, and Kaiser’s
criterion on both six and five factors for PCA-I and PCA-C re-
spectively, these are the number of factors that were retained in
the final analyses.
Table 4 shows the pattern matrices after rotation and provides
the loading values for each variable. When initial total M, P and T
(PCA-I) were included in the analysis, the items that clustered on
the same factors suggested that factor 1 represented ‘‘nutritional
status,’’ factor 2 represented ‘‘liver function,’’ factor 3 represented
‘‘acute inflammation and liver function,’’ factor 4 represented
‘‘RBC measures,’’ factor 5 represented ‘‘initial neurology,’’ and
factor 6 represented ‘‘cell measures.’’ When initial AIS M and
AIS Sens (PCA-C) were used for PCA, only five factors were
generated representing the same measures as mentioned, but with
no factor 6 representing ‘‘cell measures.’’ The resulting contri-
butions of each blood analyte to factors 1–4 were subtly different
(except for CRP) when either the individual or the overall AIS
scores were input.
Assessment of correlations between the factors generated from
PCA-I (Table 4) against outcome neurological measures revealed,
as expected, that factor 5 (initial neurology) correlated with all
outcome measures at both 3 months and 1 year follow-up (Ken-
dall’s tau ranged from 0.53 to 0.69, p< 0.001 for all correlations).
Table S2 shows that factor 1, representing ‘‘nutritional status,’’
correlated with all outcome neurology measures at 3 months except
for P, whereas factor 4, representing ‘‘RBC measures,’’ correlated
with all outcome neurology measures at 3 months except for
3 month Total M. Factors 1 and 4 also correlated with AIS M at 1
year, but factor 2 ‘‘liver function,’’ factor 3 ‘‘acute inflammation
and liver function,’’ and factor 6 ‘‘cell measures’’ did not signifi-
cantly correlate with any neurology outcome measure (Table S2).
Factors generated from PCA-C (Table 4) were also correlated
with outcome neurology measures and again, factor 5 (initial
neurology) correlated with all outcome measures at both 3 and
12 month follow-up (Kendall’s tau ranged from 0.53 to 0.88,
p < 0.001 for all correlations). As found previously, factor 1, re-
presenting ‘‘nutritional status,’’ correlated with all outcome neu-
rology measures at 3 months except for P, but factor 4, representing
‘‘RBC measures,’’ correlated with all outcome neurology measures
at 3 months (Table S2). As before, factors 1 and 4 correlated with
AIS M at 1 year, but factor 2 ‘‘liver function’’ and factor 3 ‘‘acute
inflammation and liver function’’ did not significantly correlate
with any neurology outcome measures.
Multiple regression models were utilized to produce predic-
tive models of neurological outcome following SCI at*3 and 12
months post-injury (Table 5 and Table S3). These models included
many of the clinical variables described in Table 1 (all clinical
features not in italics); for example: age, gender, injury level,
polytrauma, smoking, the existence of additional conditions, and
medications that could affect blood analytes. In all predictive
models for neurological outcome (Table 5 and Table S3), the main
contributing factor was Step 1, ‘‘initial neurology’’ + ‘‘constant,’’
(R2 range 0.5–0.766). When factors from PCA-I were used in the
predictive model, factors relating to ‘‘liver function’’ and ‘‘acute
inflammation and liver function’’ were found to be significant in the
predictive models of all sensory neurological outcomes at 3 months
(Table S3). In contrast, no factors relating to the blood analytes
were found to be predictive for neurological outcome measures
relating to motor function at either 3 or 12 months post-injury.
Clinical variables such as age, level of injury, vertebral fracture,
CCS, drinking, and smoking were also found to have a significant
influence on the various outcome measures in the predictive models
(Table S3).
Similarly, when factors from PCA-C were used in the predictive
model, ‘‘liver function’’ and ‘‘acute inflammation and liver func-
tion’’ were again predictive at 3 months for sensory neurological
outcome, with ‘‘acute inflammation and liver function’’ still being
predictive at 1 year, but only for the pain outcome score (Table 5).
Additionally, at 1 year, the ‘‘liver function’’ factor was predictive
for Total M (Table 5). The same clinical variables, as previously
found in the predictive model using the individual initial neurology
scores (Table S3), were found to have a significant influence on the
various outcome measures when the combined AIS neurology
scores were used (Table 5). The significant contribution of the
‘‘liver function’’ and ‘‘acute inflammation and liver function’’
factors to the predictive models in Tables 5 and S3 ranged from R2
of 0.013 to R2 of 0.025, with the greatest R2 (0.025) occurring in the
predictive model for 1 year pain outcome neurology (Table 5). In
some models both ‘‘liver function’’ and ‘‘acute inflammation and
liver function’’ factors were predictive; the best combined R2 im-
provement (0.043) from these factors was observed in the predic-
tive model for 3 month pain (Table 5).
Although the number of participants was too small to adequately
power an assessment of the predictive utility of the individual blood
analytes, when the individual blood analytes were input into the
predictive model alongside initial combined neurology scores and
clinical variables to predict the combined AIS outcome neurology
at 3 and 12 months, there were some individual blood analytes that
significantly predicted outcome neurology (Table S4). ALT,
magnesium, and GGT were predictive for 3 month AIS motor score
with ALT remaining predictive at 1 year for AIS motor. Total
bilirubin was also found to be predictive at 1 year for AIS motor,
whereas only calcium was predictive for AIS sensory score at 3
months. Other clinical factors found to be predictive for outcome
neurology are indicated in Table S4.
Discussion
In this study, we have analyzed a plethora of routinely gathered
blood analyte data in a cohort of SCI patients and compared this to
longitudinal neurological outcome measures following SCI. In
order to use multiple regression analysis as a reliable predictive
tool, one needs at least 10–20 times as many observations as there
are independent variables, otherwise there can be ‘‘overfitting’’ of
the data. As there were 30 blood analytes in this study, and only 82
patients (ideally ‡300 patients would have been used), PCA was
conducted to see whether the blood and neurology measures could
be reduced into factors enabling a more robust predictive model to
be generated from the data. This meant that the contributions of
some blood analytes to the factors were not included, and their
individual contribution to the predictive model was not fully ad-
dressed. We anticipate that future studies, with increased patient
numbers, will have the capability to fully elucidate the impact of all
the individual blood analytes routinely measured in SCI patients.
The purpose of the current study was to provide an indication as to
which blood analytes may have the most potential for future use in
predictive neurological outcome models.
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With respect to correlations between measures and outcomes,
previous studies have linked hypokalemia with trauma.26 There-
fore, our observed correlation between potassium and total motor
score at 3 months is not unexpected. In a previous study involving
591 SCI patients, albumin was suggested to be an independent
marker of long-term neurological outcome,27 which may explain
the correlation with 3 month outcome measures (except for pain
scores). Other literature has also found notable alterations to RBC,
hemoglobin, and hematocrit values in non-traumatic SCI, and has
found that lymphocytes decreased over time in traumatic SCI.28
Interestingly, none of the components of the ‘‘liver function’’ and
‘‘acute inflammation and liver function’’ factors, which were the
only factors to add predictive value to the outcome models in this
study, directly correlated with any outcome measures. This high-
lights the importance of taking into account clinical factors that
might impact the patient’s outcome neurology and blood measures
in generating a predictive model. An ideal predictive model for
outcome neurology in SCI patients would also take into account the
patient’s body mass index (BMI) and perhaps other information
such as ‘‘dry’’ biomarker data garnered from clinical imaging.
The predictive model generated in our study based on the PCA
analysis found that the ‘‘liver function’’ factor, which is made up of
AP, ALT, and GGT, and the ‘‘acute inflammation and liver func-
tion’’ factor, composed of CRP and total bilirubin, added prog-
nostic value to this model. However, it needs to be noted that
although these factors added significant value to the models, the
greatest R2 achieved was only 4%. Nonetheless, it appears that
blood analytes related to liver function may have the potential to
significantly predict neurological outcome for SCI patients. In
particular, when we ran the model with the individual analytes, one
of the contributing analytes in the ‘‘liver function’’ factor, ALT,
appeared to be the most predictive (R2 = 15%) of the blood mea-
sures, although it must be stressed that this analysis is not statisti-
cally robust, because of the small cohort sample size. It may be
possible that the lack of patients in this study, and hence the use of
PCA, may have reduced the effects of individual analytes. In fact,
the PCA resulted in some blood analytes not being considered in the
predictive model. The findings of this study will form the basis of a
future study in which a considerably larger data set (* 500 pa-
tients) is being collected. In this follow-on study, PCA may not be
necessary, and the analytes will be assessed individually for their
predictive potential.
ALT is an enzyme released from damaged hepatocytes, and is a
key clinical marker of fatty liver disease.29 This study found it to be
the only routine blood measure to predict neurological outcome in
the form of AIS motor score at both 3 and 12 months (Table S4).
Further, when grouped by PCA, ‘‘liver function’’ markers (AP,
ALT, GGT) were predictive of neurological outcome, as were total
bilirubin and CRP in the second predictive group ‘‘acute inflam-
mation and liver function.’’ SCI is known to lead to a systemic
inflammatory response that can result in secondary organ compli-
cations, particularly in the liver, lungs, and kidneys.30–33 In addi-
tion, a rat contusion model study found ALT to be significantly
raised in the 21 days following injury, coupled with excess lipid
accumulation and increased expression of pro-inflammatory
genes.34 Interestingly, this study also detected liver inflammation
following lumbar SCI,34 whereas previous studies in rats had
shown that liver inflammation can occur within 30 min of SCI,35
and that its severity correlates with level of injury.31 AP, another
analyte of the predictive ‘‘liver function’’ factor, is an enzyme that
plays a significant role in bone mineralization, and has four iso-
enzymes, which are intestinal (IAP), placental (PLAP), germinal
(GCAP), and tissue nonspecific (TNAP).36–40 TNAP is the most
abundant isoenzyme in the blood and is primarily derived from the
bone, kidneys, and liver, but is also found in neuronal tissue.41
Higher levels of AP have been associated with the presence of
heterotopic ossification (HO) following SCI,42 although other,
smaller studies have found no association.43,44 HO occurs in*20%
of SCI patients,45 and its presence may impact on both rehabilita-
tion and outcome measures for the patient. No note of this clinical
feature was made during this study, but HO potentially needs to be
recorded for future blood biomarker studies. TNAP has been shown
to be elevated in Alzheimer’s disease and in brain injury pa-
tients.46,47 A TBI study using a rat blast and weight drop model
found that the injury resulted in a decrease in TNAP expression and
activity in the brain and plasma at 6 and 24 h post- injury.48 Further,
exogenous administration of AP has been shown to be beneficial,
including improvements to renal function, for inflammatory dis-
orders, such as sepsis, in humans and in murine models, and hence
is worthy of further investigation in SCI patients.49,50
GGT, the final component of the predictive ‘‘liver function’’
factor, is a liver enzyme found on the plasma membrane of most
cells and organ tissues, and it is frequently used as a marker for liver
disease and more recently, many other conditions such as cardio-
vascular disease.51–53 Little is known of the possible role of GGT
following SCI, but positive correlations between GGT and age,
BMI, smoking, and alcohol consumption have been identified.54,55
In vivo and in vitro studies have also found overexpression of GGT
to have a harmful effect on bone metabolism by accelerating bone
reabsorption and causing osteoporosis.56,57 Another study analyzed
the serum of 2415 Finnish men with good cognitive function, and
found GGT to be positively associated with future risk of demen-
tia.58 It has been proposed that GGT may contribute to dementia
risk and poorer bone metabolism because of its pro-inflammatory
and pro-oxidative properties.59 Future studies could compare GGT
levels before and after SCI to establish whether elevated GGT
before injury is associated with worse recovery.
The second factor found to have prognostic value from the PCA
analysis was the ‘‘acute inflammation and liver function’’ factor,
which consists of total bilirubin and CRP. Bilirubin is the break-
down product of heme and circulates in plasma conjugated to al-
bumin until it is processed by hepatocytes and ultimately excreted
from the body. The aforementioned systemic inflammation that
follows traumatic SCI and impacts liver function is likely to in-
fluence blood bilirubin levels.30–32 CRP is one of the key proteins in
the acute inflammatory response.60 However, CRP is more spe-
cifically known to be indicative of acute infection, as opposed to the
chronic low-grade inflammation associated with atherosclerosis,
for example.61–63 CRP levels have been shown to be elevated in
SCI patients in the absence of infection and regardless of injury
level or duration, when compared with able-bodied controls.64
Other pro-inflammatory cytokines such as tumor necrosis factor
alpha (TNF-a) have been found to be elevated in the serum of SCI
patients compared with uninjured controls during the subacute
phase of injury (2–52 weeks post-injury).65 Further, patients who
had lower TNF-a at 9 h post-injury experienced improved neuro-
logical function compared with SCI patients with higher TNF-a.66
These results suggest that inflammatory markers may hold prog-
nostic value for the neurological progression of SCI.
As four out of the five analytes that make up the two PCA
components that were found to be predictive of neurological out-
come are markers of liver function, and the remaining analyte is
reflective of inflammatory status, this suggests that the liver may
play a greater role in recovery following SCI than has been
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previously appreciated. However, a limitation of this study is the
relatively small sample size of 82 patients. In order to perform more
robust modelling of the data such that a reliable prognostic model
can be built, further studies with increased patient numbers are
required.67 Additionally, future studies may wish to incorporate
additional data, such as obesity, omics (proteomics, metabolomics
transcriptomics), and clinical imaging, which may help enhance the
models’ predictive strength. The low-grade systemic inflammation
associated with obesity in particular, may be an important con-
founding variable for additional prognostic models.68–70 In future
larger studies, the focus will be on improving neurological out-
come prediction, which is likely to be most useful for patients with
AIS B and C SCI, because of the decreased power of the initial
AIS score in predicting outcome in these subsets of SCI patients.71
Further, there is scope to assess whether adjusting some of these
routine measures improves outcomes for SCI patients. However,
whether a targeted approach to alter the levels of these molecules
can cause a concurrent change in a SCI patient’s neurological
outcome remains to be assessed, in appropriate randomized con-
trolled clinical trials.
Conclusion
The results from this preliminary study suggest that routine
blood analytes when statistically incorporated into ‘‘linked’’
factors can provide prognostic value for AIS motor and sensory
score in SCI patients at 3 and 12 months post-injury. In particular,
markers of liver function were found to add the most predictive
value. This indicates that maintaining a healthy liver function
acutely following SCI may be a key rehabilitative target in order
to achieve optimal neurological recovery in the long term. These
findings need to be corroborated with a larger cohort of SCI
patients before a prognostic model of this type can be suggested
for clinical use.
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